Claims
- 1. A method of in situ detecting localization and distribution of heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting the localization and distribution of said detectable heparanase specific molecular probe.
- 2. The method of claim 1, wherein said biological sample is selected from the group consisting of cells and tissues.
- 3. The method of claim 1, wherein said biological sample is malignant.
- 4. The method of claim 3, wherein said malignancy is selected from the group consisting of a solid tumor and a hematopoietic tumor.
- 5. The method of claim 4, wherein said solid tumor is selected from the group consisting of carcinoma, adenocarcinoma, squameous cell carcinoma, teratocarcinoma, mesothelioma and melanoma, and further wherein said hematopoietic tumor is selected from the group consisting of lymphoma and leukemia.
- 6. The method of claim 4, wherein said solid tumor is a primary tumor, or a metastasis thereof, and is originated from an organ selected from the group consisting of liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus, pancreas.
- 7. The method of claim 1, wherein said detectable heparanase specific molecular probe is selected from the group consisting of a nucleic acid sequence hybridizable with heparanase encoding nucleic acid and an anti-heparanase antibody capable of specifically binding heparanase.
- 8. The method of claim 7, wherein said nucleic acid sequence hybridizable with heparanase encoding nucleic acid is selected from the group consisting of a synthetic oligonucleotide, an antisesnse heparanase RNA and heparanase DNA, labeled by a detectable moiety.
- 9. A method of detecting heparanase protein in a body fluid of a patient comprising the steps of reacting said body fluid with an anti-heparanase antibody and monitoring said reaction.
- 10. The method of claim 9, wherein said body fluid is selected from the group consisting of plasma, urine, pleural effusions and saliva.
- 11. The method of claim 9, wherein said body fluid is of a patient suffering from a condition selected from the group consisting of cancer, renal disease, diabetes and inflammation.
- 12. The method of claim 11, wherein said renal disease is associated with diabetes.
- 13. The method of claim 9, wherein said anti-heparanase antibody is selected from the group consisting of a monoclonal antibody and a poly clonal antibody.
- 14. The method of claim 9, wherein reacting said body fluid with said anti-heparanase antibody is effected in solution.
- 15. The method of claim 9, wherein reacting said body fluid with said anti-heparanase antibody is effected on a substrate capable of adsorbing proteins present in said body fluid.
- 16. The method of claim 9, wherein said body fluid is of a patient suffering from myeloma, breast carcinoma, metastatic breast carcinoma, hemorrhagic nephritis, nephrotic syndrome, normoalbuminuric type I diabetes, microalbuminuric type I diabetes, kidney disorder, inflammation, sepsis, inflammatory and autoimmune disease.
- 17. A method of detecting the presence, absence or level of heparanase transcripts in a biological sample comprising the steps of:
(a) extracting messenger RNA from the biological sample, thereby obtaining a plurality of messenger RNAs; (b) reverse transcribing said plurality of messenger RNAs into a plurality of complementary DNAs; (c) contacting said plurality of complementary DNAs with a pair of heparanase specific polymerase chain reaction primers, nucleoside triphosphates and a thermostable DNA polymerase; (d) performing a polymerase chain reaction; and (e) detecting the presence, absence or level of said polymerase chain reaction product.
- 18. A method of detecting heparanase messenger RNA in a biological sample comprising the steps of reverse transcribing the messenger RNA into complementary DNA, contacting said complementary DNA with polymerase chain reaction oligonucleotides hybridizable to heparanase encoding nucleic acid, performing a polymerase chain reaction and monitoring for heparanase specific polymerase chain reaction products.
- 19. A method of detecting the presence, absence or level of heparanase protein in a biological sample comprising the steps of:
(a) extracting proteins from the biological sample, thereby obtaining a plurality of proteins; (b) size separating said proteins; (c) interacting said size separated proteins with an anti-heparanase antibody; and (d) detecting the presence, absence or level of said interacted anti-heparanase antibody.
- 20. The method of claim 19, wherein said anti-heparanase antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.
- 21. The method of claim 19, wherein said size separation is effected by electrophoresis.
- 22. A method of targeted drug delivery to a tissue of a patient, the tissue expressing heparanase, the method comprising the steps of providing a complex of a drug directly or indirectly linked to an anti-heparanase antibody and administering said complex to the patient.
- 23. A method of treating a patient having a condition associated with heparanase expression comprising the step of administering an anti-heparanase antibody to the patient.
- 24. An oligonucleotide comprising a nucleic acid sequence specifically hybridizable with heparanase encoding nucleic acid.
- 25. An antisense nucleic acid molecule comprising a nucleic acid sequence specifically hybridizable with heparanase messenger RNA.
- 26. A sense nucleic acid molecule comprising a nucleic acid sequence specifically hybridizable with heparanase antisense RNA.
- 27. A pair of polymerase chain reaction primers comprising a sense primer and an antisense primers, each of said primers including a nucleic acid sequence specifically hybridizable with heparanase encoding nucleic acid.
- 28. The use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression.
- 29. The use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase.
- 30. The use of a heparanase specific molecular probe for quantification of heparanase in a body fluid.
- 31. The use of a heparanase specific molecular probe for targeted drug delivery.
- 32. The use of a heparanase specific molecular probe as a therapeutic agent.
- 33. A method of detecting heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting said detectable heparanase specific molecular probe.
Parent Case Info
[0001] This is a divisional of U.S. patent application Ser. No. 09/071,739, filed May 1, 1998, which is a continuation-in-part of U.S. patent application Ser. No. 08/922,170, filed Sep. 2, 1997.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09071739 |
May 1998 |
US |
Child |
09322977 |
Jun 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08922170 |
Sep 1997 |
US |
Child |
09071739 |
May 1998 |
US |